Highest development stage: Approved by FDA in 1946

Development status: Approved, off-patent

Gram-positive activity

Gram-negative activity

Mechanism of Action/Target pathogen: Inhibits protein synthesis by binding to the 30S subunit of the bacterial ribosome. Active against Gram-positive (incl. Mycobacterium tuberculosis) and Gram-negative bacteria

Additional information: Streptomyces natural compound; human use in tuberculosis in combination, used as pesticide